Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
UK drug giants in the spotlight as part of latest sector review
11:18am, Wednesday, 17'th Sep 2025
The UK's two big drugmakers came under the spotlight in Berenberg's latest review of the pharmaceuticals sector. AstraZeneca PLC (LSE:AZN) gets a clear thumbs-up with a 'buy' rating and price target
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial
03:08am, Wednesday, 17'th Sep 2025
AstraZeneca PLC (LSE:AZN) has reported positive results from a late-stage study of Saphnelo, its treatment for systemic lupus erythematosus (SLE), showing the drug was effective when given as a self-
AstraZeneca's asthma drug fails main goal of COPD study
02:13am, Wednesday, 17'th Sep 2025
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
11:39am, Monday, 15'th Sep 2025
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca shares down 3% after rating cut, UK investment pause
07:28am, Monday, 15'th Sep 2025
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
04:00am, Monday, 15'th Sep 2025
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.
AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty
02:20pm, Friday, 12'th Sep 2025
AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whi
Exclusive: AstraZeneca pauses $270 million investment in Britain
12:38pm, Friday, 12'th Sep 2025
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 09'th Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
06:02pm, Monday, 08'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca faces pivotal test as spotlight shifts to Baxdrostat's 24-hour data
07:37am, Monday, 08'th Sep 2025
AstraZeneca PLC (LSE:AZN) may have caught the market's attention last weekend with promising data on its experimental blood pressure treatment, but the follow-up analysis suggests the story is far fro
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Final Trades: AstraZeneca, Corning, the IBIT and the SPHD
01:33pm, Wednesday, 03'rd Sep 2025
The Investment Committee give you their top stocks to watch for the second half.
AstraZeneca: Buy This Pharma Star Now For Upside Potential
07:00am, Tuesday, 02'nd Sep 2025
Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the fores
